Fulgent Genetics
Fulgent Genetics Core Revenues Rise 17 Percent
Total revenues were down approximately 20 percent, which the El Monte, California-based molecular diagnostics firm attributed to a year-over-year decline in COVID-19 testing.
Fulgent Genetics Core Revenues Jump 48 Percent
The firm noted a momentum in precision diagnostics, anatomic pathology, and pharma services while declining COVID-19 revenues caused an overall revenue decline.
360Dx Top 30 Drops 6 Percent in May
Of the 30 companies in the index, 21 saw their share prices decrease, while nine saw their stock prices rise.
Fulgent Genetics Raises Guidance After Strong Jump in Q1 Core Revenues
As a result of the strong core growth, the company raised its full-year revenue guidance to $250 million from previous guidance of $240 million.
Fulgent Genetics Q4 Revenues Fall 73 Percent, Beat Expectations
The firm said its non-COVID core revenues nearly doubled for the quarter as well as for full-year 2022.
Sep 1, 2022
360Dx Top 30 Tumbles in August
Apr 21, 2022
Jan 4, 2022
360Dx Index Rises 20 Percent in 2021
Aug 10, 2021